As many as 2 million people have been exposed to carcinogens in several generic blood pressure drugs; flu activity has worsened over the past week; and real-world data is changing how researchers study drug efficacy and safety.
The FDA has warned that as many as 2 million people worldwide could have been exposed to probable human carcinogens in a class of generic blood pressure medications, and at least half of these people taking the medications are in the United States. According to The Wall Street Journal, the contaminated drugs include valsartan, irbesartan, and losartan. However, the band name versions of these medications are not affected, nor are all generic products.Since October, there have been approximately 11.4 million 5.4 million doctor visits, and 136,000 flu hospitalizations, reported CNN. While this flu season is poised to be milder than last, flu activity has worsened over the past week, with an additional 3 children dying due to flu-related causes. There have been a total of 22 flu-related deaths this season.
The use of real-world evidence is changing how researchers determine the safety and efficacy of drugs. When drugs are used in clinical practice following trials and FDA approval, they are often used in settings different from those studied in the trials. According to STAT News, it’s time for biotech and pharmaceutical companies to pay more attention to and understand real-world studies, a position that has been backed by FDA Commissioner Scott Gottlieb, MD.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More